
Elliot Norry MD FACP
Gastroenterology
Adaptimmune, Chief Medical Officer
Join to view full profile
351 Rouse BlvdPhiladelphia, PA 19112
Phone+1 215-825-9260
Dr. Norry is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Gastroenterology, 1993 - 1995
Temple University HospitalResidency, Internal Medicine, 1989 - 1992
New York University School of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1991 - 2026
Publications & Presentations
PubMed
- 7 citationsPhase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.Tim Meyer, Richard S Finn, Mitesh Borad, Amit Mahipal, Julien Edeline
Journal of Hepatology. 2026-01-01 - 145 citationsAfamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia
Lancet. 2024-04-13 - 4 citationsDurable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.Kewen He, David S Hong, Danxia Ke, Partow Kebriaei, Tianjiao Wang
Melanoma Research. 2023-08-01
Journal Articles
- Fludarabine and Neurotoxicity in Engineered T-cell TherapyElliot Norry, Crystal L Mackall, Nature
Press Mentions
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-Cel in Synovial Sarcoma - Response Rate and Durability Remain ConsistentNovember 18th, 2022
Adaptimmune Reports Positive Results from Its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOSNovember 11th, 2021
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC MeetingsOctober 5th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









